MedTrace Logo

A Study of E7130 in Participants With Solid Tumors

NCT03444701 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-03-06

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with solid tumors.

Conditions

Interventions

DRUG

E7130

Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.

DRUG

E7130

Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-05
Primary Completion
2024-12-27
Completion
2024-12-27

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03444701 on ClinicalTrials.gov